### Calculation-based Self-Assessment Questions (HE 1‚ÄìHE 12)

These questions test **quantitative applications** of health economics concepts from **HE 1‚ÄìHE 12**, requiring calculations and, where specified, graph drawing to visualize results. Each question is designed to reflect key themes such as **market dynamics**, **financing**, **insurance**, **equity**, **economic evaluation**, **appraisal**, and **policy application**, with Malaysia-specific contexts where relevant.

1. **ICER Calculation for a New Cancer Drug (HE 9, HE 10, HE 12)**  
   A new targeted therapy for lung cancer costs RM 120,000 per patient annually and yields 2.8 Quality-Adjusted Life Years (QALYs), while standard care costs RM 50,000 per patient annually and yields 2.0 QALYs. Malaysia‚Äôs Willingness-to-Pay (WTP) threshold is RM 100,000 per QALY.  
   - **Task**:  
     a. Calculate the **ICER** in RM per QALY.  
     b. Determine if the new therapy is cost-effective based on the WTP threshold.  
     c. Plot a **cost-effectiveness plane** to visualize the ICER, labeling the axes, quadrants, and the intervention‚Äôs position.  
   - **Formula**:  
     $$\text{ICER} = \frac{\text{Cost}_{\text{new}} - \text{Cost}_{\text{comparator}}}{\text{Effect}_{\text{new}} - \text{Effect}_{\text{comparator}}}$$

2. **Discounting Future Costs for a Vaccination Program (HE 10)**  
   A national HPV vaccination program incurs a cost of RM 150,000 in year 5 to prevent cervical cancer cases. Use a discount rate of 3% to calculate the present value of this cost.  
   - **Task**:  
     a. Calculate the **present value** of the cost, rounded to two decimal places.  
     b. Explain how discounting impacts the cost-effectiveness analysis for long-term preventive interventions.  
     c. Create a **line graph** showing the discounted cost over years 1‚Äì5 at a 3% discount rate.  
   - **Formula**:  
     $$\text{Present Value} = \frac{\text{Future Value}}{(1 + r)^n}$$  
     where \( r \) is the discount rate and \( n \) is the number of years.

3. **Budget Impact Analysis for Diabetes Screening (HE 12)**  
   A Type 2 diabetes screening program has an ICER of RM 95,000 per QALY, costs RM 200 per person screened, and targets 1.5 million adults annually. The alternative is treating diabetes complications at RM 5,000 per case, with 2,000 cases expected annually without screening.  
   - **Task**:  
     a. Calculate the **total budget impact** of the screening program.  
     b. Calculate the **total cost** of treating complications without screening.  
     c. Determine the **net budget impact** (savings or additional cost) of implementing the screening program.  
     d. Plot a **bar graph** comparing the total costs of screening vs. treatment, labeling costs and scenarios.

4. **Sensitivity Analysis for a Hypertension Drug (HE 10, HE 11)**  
   A study evaluates a new hypertension drug with a base-case ICER of RM 80,000 per QALY. A one-way sensitivity analysis varies the drug cost by ¬±20% (base cost: RM 60,000; range: RM 48,000‚ÄìRM 72,000), resulting in ICERs of RM 64,000 and RM 96,000, respectively. Malaysia‚Äôs WTP threshold is RM 100,000 per QALY.  
   - **Task**:  
     a. Calculate the **percentage change** in the ICER for each cost variation.  
     b. Determine if the drug remains cost-effective across the cost range.  
     c. Create a **tornado diagram** to visualize the impact of drug cost variation on the ICER, labeling the base case and range.  
   - **Formula**:  
     $$\text{\% Change} = \frac{\text{New ICER} - \text{Original ICER}}{\text{Original ICER}} \times 100\%$$

5. **DRG Costing for Hospital Admissions (HE 12)**  
   A Malaysian hospital uses DRG/case-mix costing with a base rate of RM 4,000 in 2025, calculated from a hospital budget of RM 40 million and 10,000 patient cases in 2024. Two DRG groups are considered: Appendectomy (cost weight = 0.85) and Stroke (cost weight = 1.7).  
   - **Task**:  
     a. Verify the **base rate** using the provided formula.  
     b. Calculate the **cost per case** for Appendectomy and Stroke DRGs.  
     c. Plot a **bar graph** comparing the costs of the two DRG groups, labeling the groups and costs.  
   - **Formula**:  
     $$\text{BR}_t = \frac{\text{HP}_t}{\text{Cases}_{h,t-1}}$$

6. **Supply and Demand for Influenza Vaccines**  
   The Malaysian Ministry of Health (MOH) is planning a quadrivalent influenza vaccine (QIV) program for 600,000 elderly (‚â•60 years). Without intervention, the market price is RM 150 per dose, with an equilibrium quantity of 250,000 doses. A full subsidy reduces the price to RM 0, increasing demand to 700,000 doses. A price ceiling of RM 70 is proposed.  
	**Tasks**:  
	a) Draw and label the **initial supply and demand curves**, marking the equilibrium price (RM 150) and quantity (250,000 doses). (5 marks)  
	b) Draw and label the **new curves after the full subsidy**, showing the demand shift and new equilibrium quantity (700,000 doses). Assume the supply curve is unchanged. (5 marks)  
	c) Calculate the **change in quantity demanded** due to the subsidy and explain its impact on private providers selling at RM 150. (5 marks)  
	d) Analyze the **price ceiling** (RM 70) effects on supply, demand, and elderly access, considering **equity** for low-income groups. (10 marks)

---

### Complete Answer Guide for Calculation-based Questions

Below is a detailed answer guide for each question, including **formulas**, **calculations**, **graph plotting instructions**, and **explanations**, with cross-references to relevant lectures (HE 1‚ÄìHE 12) and Malaysia‚Äôs healthcare context.

#### Question 1: ICER Calculation for a New Cancer Drug (HE 9, HE 10, HE 12)

**Task**:  
a. Calculate the **ICER** in RM per QALY.  
b. Determine if the new therapy is cost-effective based on the WTP threshold of RM 100,000 per QALY.  
c. Plot a **cost-effectiveness plane** to visualize the ICER, labeling the axes, quadrants, and the intervention‚Äôs position.

**Answer**:

**a. Calculate the ICER**  
- **Data**:  
  - New targeted therapy: Cost = RM 120,000, QALYs = 2.8  
  - Standard care: Cost = RM 50,000, QALYs = 2.0  
- **Formula**:  
  $$\text{ICER} = \frac{\text{Cost}_{\text{new}} - \text{Cost}_{\text{comparator}}}{\text{Effect}_{\text{new}} - \text{Effect}_{\text{comparator}}}$$  
- **Calculation**:  
  - Incremental cost = RM 120,000 - RM 50,000 = RM 70,000  
  - Incremental QALYs = 2.8 - 2.0 = 0.8 QALYs  
  - $$\text{ICER} = \frac{70,000}{0.8} = 87,500 \, \text{RM per QALY}$$

**b. Cost-Effectiveness Determination**  
- **WTP Threshold**: RM 100,000 per QALY (HE 12, Section 4).  
- **Comparison**: The ICER of RM 87,500 per QALY is **below** the WTP threshold, indicating that the new therapy is **cost-effective** for Malaysia‚Äôs health system, such as for **MaHTAS** evaluations (HE 12, Section 4; HE 9, Section 3). However, **budget impact** and **equity** must also be considered, as a low ICER does not guarantee affordability or equitable access, especially given Malaysia‚Äôs high OOP reliance (31.5% of THE, HE 4, Section 9) (HE 12, Section 6). For instance, high out-of-pocket costs could limit access for low-income patients, aligning with **HE 6**‚Äôs focus on addressing **health inequities** (HE 6, Section 2).

**c. Plotting the Cost-Effectiveness Plane**  
- **Description**: The cost-effectiveness plane visualizes the incremental cost (y-axis) versus incremental effectiveness (x-axis), with quadrants indicating different cost-effectiveness scenarios (HE 10, Section 10; HE 12, Section 3).  
- **Axes**:  
  - X-axis: Incremental QALYs (Effectiveness), ranging from -1 to 1 QALYs.  
  - Y-axis: Incremental Costs (RM), ranging from -100,000 to 100,000.  
  - Origin (0,0): Represents the comparator (standard care).  
- **Quadrants**:  
  - **Quadrant I (NE)**: Higher cost, higher effectiveness (where the new therapy lies).  
  - **Quadrant II (NW)**: Lower cost, higher effectiveness (dominant).  
  - **Quadrant III (SW)**: Lower cost, lower effectiveness.  
  - **Quadrant IV (SE)**: Higher cost, lower effectiveness (dominated).  
- **Position**: Plot a point at (0.8 QALYs, RM 70,000) in Quadrant I, representing the new therapy‚Äôs incremental QALYs and costs.  
- **Instructions for Plotting**:  
  1. Draw a Cartesian plane with the x-axis labeled ‚ÄúIncremental QALYs‚Äù and the y-axis labeled ‚ÄúIncremental Costs (RM).‚Äù  
  2. Mark the origin (0,0) as the comparator (standard care).  
  3. Divide the plane into four quadrants, labeling them (NE, NW, SW, SE).  
  4. Plot the point (0.8, 70,000) in Quadrant I, labeling it ‚ÄúNew Therapy.‚Äù  
  5. Add a dashed line representing the WTP threshold (slope = RM 100,000 per QALY, e.g., y = 100,000x) to show the cost-effectiveness boundary.  
  6. Indicate that the point lies below the threshold line, confirming cost-effectiveness.  
- **Explanation**: The point in Quadrant I shows that the new therapy is more costly and more effective than standard care (HE 10, Section 7). Its position below the WTP threshold line confirms cost-effectiveness, supporting its potential inclusion in Malaysia‚Äôs **MyHEALTH formulary**, though **budget impact** (e.g., scaling to a large population) and **equity** (e.g., access for rural patients) must be assessed (HE 12, Sections 6, 9; HE 6, Section 2).

#### Question 2: Discounting Future Costs for a Vaccination Program (HE 10)

**Task**:  
a. Calculate the **present value** of the cost (RM 150,000 in year 5) at a 3% discount rate, rounded to two decimal places.  
b. Explain how discounting impacts the cost-effectiveness analysis for long-term preventive interventions.  
c. Create a **line graph** showing the discounted cost over years 1‚Äì5 at a 3% discount rate.

**Answer**:

**a. Calculate the Present Value**  
- **Data**: Future Value (FV) = RM 150,000, Year (n) = 5, Discount Rate (r) = 3% (0.03).  
- **Formula**:  
  $$\text{Present Value} = \frac{\text{Future Value}}{(1 + r)^n}$$  
- **Calculation**:  
  - $$\text{PV} = \frac{150,000}{(1 + 0.03)^5} = \frac{150,000}{(1.03)^5}$$  
  - $$(1.03)^5 = 1.03 \times 1.03 \times 1.03 \times 1.03 \times 1.03 \approx 1.159274$$  
  - $$\text{PV} = \frac{150,000}{1.159274} \approx 129,398.66$$  
  - **Present Value**: RM 129,398.66 (rounded to two decimal places).

**b. Impact of Discounting on Cost-Effectiveness Analysis**  
- **Explanation**: Discounting adjusts future costs and outcomes to their present value, reflecting **time preference** where immediate costs/benefits are valued more than future ones (HE 10, Section 6). For long-term preventive interventions like HPV vaccination, discounting reduces the present value of future costs (e.g., RM 150,000 to RM 129,398.66) and benefits (e.g., QALYs gained from prevented cancers), impacting the **ICER** (HE 10, Section 7). This ensures fair comparisons with immediate-cost interventions, as seen in Malaysia‚Äôs **MaHTAS** evaluations, where a 3% discount rate is standard (HE 10, Section 6). However, high discounting can undervalue long-term preventive benefits, potentially biasing against programs like vaccinations that address **health inequities** (e.g., cervical cancer in rural women, HE 6, Section 2). Policymakers must balance this with **budget impact** and **equity** considerations to support **UHC** goals (HE 12, Section 6; HE 5, Section 9).

**c. Plotting the Line Graph**  
- **Description**: The line graph shows the discounted cost of RM 150,000 over years 1‚Äì5 at a 3% discount rate, illustrating how present value decreases over time (HE 10, Section 6).  
- **Calculations for Years 1‚Äì5**:  
  - Year 1: $$\text{PV} = \frac{150,000}{(1.03)^1} \approx 145,631.07$$  
  - Year 2: $$\text{PV} = \frac{150,000}{(1.03)^2} \approx 141,389.39$$  
  - Year 3: $$\text{PV} = \frac{150,000}{(1.03)^3} \approx 137,271.25$$  
  - Year 4: $$\text{PV} = \frac{150,000}{(1.03)^4} \approx 133,272.86$$  
  - Year 5: $$\text{PV} = \frac{150,000}{(1.03)^5} \approx 129,398.66$$  
- **Axes**:  
  - X-axis: Time (Years 0‚Äì5).  
  - Y-axis: Present Value (RM, ranging from 120,000 to 150,000).  
- **Instructions for Plotting**:  
  1. Draw a line graph with the x-axis labeled ‚ÄúTime (Years)‚Äù (0 to 5) and the y-axis labeled ‚ÄúPresent Value (RM)‚Äù (120,000 to 150,000).  
  2. Plot points: (0, 150,000), (1, 145,631.07), (2, 141,389.39), (3, 137,271.25), (4, 133,272.86), (5, 129,398.66).  
  3. Connect the points with a smooth line to show the decline in present value over time.  
  4. Label the graph ‚ÄúDiscounted Cost of HPV Vaccination Program (3% Discount Rate).‚Äù  
- **Explanation**: The downward trend illustrates the effect of discounting, where future costs lose value over time, critical for long-term interventions like vaccinations (HE 10, Section 6). This visualization helps policymakers understand the reduced present value of future costs, supporting **MaHTAS** evaluations and **UHC** planning (HE 12, Section 10).

#### Question 3: Budget Impact Analysis for Diabetes Screening (HE 12)

**Task**:  
a. Calculate the **total budget impact** of the screening program.  
b. Calculate the **total cost** of treating complications without screening.  
c. Determine the **net budget impact** (savings or additional cost) of implementing the screening program.  
d. Plot a **bar graph** comparing the total costs of screening vs. treatment, labeling costs and scenarios.

**Answer**:

**a. Total Budget Impact of Screening Program**  
- **Data**: Cost per person = RM 200, Target Population = 1.5 million adults.  
- **Calculation**:  
  - Total Budget Impact = Cost per person √ó Population  
  - $$200 \times 1,500,000 = 300,000,000$$  
  - **Total Budget Impact**: RM 300,000,000.

**b. Total Cost of Treating Complications Without Screening**  
- **Data**: Cost per case = RM 5,000, Expected cases = 2,000.  
- **Calculation**:  
  - Total Cost = Cost per case √ó Number of cases  
  - $$5,000 \times 2,000 = 10,000,000$$  
  - **Total Cost**: RM 10,000,000.

**c. Net Budget Impact**  
- **Calculation**:  
  - Net Budget Impact = Total Budget Impact (Screening) - Total Cost (Treatment)  
  - $$300,000,000 - 10,000,000 = 290,000,000$$  
  - **Net Budget Impact**: Additional cost of RM 290,000,000.  
- **Explanation**: The screening program incurs an additional cost of RM 290 million compared to treating complications without screening, reflecting a significant **budget impact** despite its cost-effective ICER (RM 95,000 per QALY, below Malaysia‚Äôs WTP threshold of RM 100,000, HE 12, Section 6). This aligns with **HE 12**‚Äôs emphasis on balancing **cost-effectiveness** with **affordability** and **fiscal space** (HE 12, Section 6). The high cost could strain Malaysia‚Äôs public health budget (2021 THE: RM 78.2 billion, HE 4, Section 9), requiring consideration of **equity** (e.g., targeting high-risk rural populations, HE 6, Section 2) and **feasibility** (e.g., IT infrastructure needs, HE 12, Section 5).

**d. Plotting the Bar Graph**  
- **Description**: The bar graph compares the total costs of the screening program (RM 300 million) and treatment without screening (RM 10 million), highlighting the budget impact (HE 12, Section 6).  
- **Axes**:  
  - X-axis: Scenarios (‚ÄúScreening Program,‚Äù ‚ÄúTreatment Without Screening‚Äù).  
  - Y-axis: Total Cost (RM, ranging from 0 to 350,000,000).  
- **Instructions for Plotting**:  
  1. Draw a bar graph with the x-axis labeled ‚ÄúScenarios‚Äù and the y-axis labeled ‚ÄúTotal Cost (RM).‚Äù  
  2. Create two bars:  
     - ‚ÄúScreening Program‚Äù at RM 300,000,000.  
     - ‚ÄúTreatment Without Screening‚Äù at RM 10,000,000.  
  3. Label each bar with its cost value (e.g., ‚ÄúRM 300M,‚Äù ‚ÄúRM 10M‚Äù).  
  4. Title the graph ‚ÄúBudget Impact: Diabetes Screening vs. Treatment Without Screening.‚Äù  
- **Explanation**: The bar graph visually emphasizes the significant cost difference, with screening being 30 times more expensive than treatment alone, highlighting the **budget impact** challenge (HE 12, Section 6). This visualization aids policymakers in assessing **fiscal space** and prioritizing interventions, aligning with **MaHTAS** evaluations and **UHC** goals (HE 12, Section 10; HE 5, Section 9).

#### Question 4: Sensitivity Analysis for a Hypertension Drug (HE 10, HE 11)

**Task**:  
a. Calculate the **percentage change** in the ICER for each cost variation (¬±20% of RM 60,000).  
b. Determine if the drug remains cost-effective across the cost range, given a WTP threshold of RM 100,000 per QALY.  
c. Create a **tornado diagram** to visualize the impact of drug cost variation on the ICER, labeling the base case and range.

**Answer**:

**a. Calculate the Percentage Change in ICER**  
- **Data**:  
  - Base-case ICER = RM 80,000 per QALY, Base cost = RM 60,000.  
  - Cost variation: ¬±20% (RM 48,000‚ÄìRM 72,000).  
  - Resulting ICERs: RM 64,000 (at RM 48,000), RM 96,000 (at RM 72,000).  
- **Formula**:  
  $$\text{\% Change} = \frac{\text{New ICER} - \text{Original ICER}}{\text{Original ICER}} \times 100\%$$  
- **Calculation for Lower Cost (RM 48,000)**:  
  - New ICER = RM 64,000, Original ICER = RM 80,000  
  - $$\text{\% Change} = \frac{64,000 - 80,000}{80,000} \times 100\% = \frac{-16,000}{80,000} \times 100\% = -20\%$$  
- **Calculation for Higher Cost (RM 72,000)**:  
  - New ICER = RM 96,000, Original ICER = RM 80,000  
  - $$\text{\% Change} = \frac{96,000 - 80,000}{80,000} \times 100\% = \frac{16,000}{80,000} \times 100\% = +20\%$$  
- **Results**:  
  - Lower cost: -20% change (ICER decreases to RM 64,000).  
  - Higher cost: +20% change (ICER increases to RM 96,000).

**b. Cost-Effectiveness Across the Cost Range**  
- **WTP Threshold**: RM 100,000 per QALY (HE 12, Section 4).  
- **Comparison**:  
  - Base-case ICER (RM 80,000) is **cost-effective** (< RM 100,000).  
  - Lower cost ICER (RM 64,000) is **cost-effective** and more favorable.  
  - Higher cost ICER (RM 96,000) is **cost-effective**, as it remains below the threshold.  
- **Explanation**: The drug remains cost-effective across the cost range (RM 48,000‚ÄìRM 72,000), as all ICERs are below RM 100,000 per QALY, supporting its potential inclusion in Malaysia‚Äôs **Peka B40** program (HE 12, Section 10; HE 11, Section 10). However, **sensitivity analysis** ensures robustness, as highlighted in **HE 10** (Section 8) and **HE 11**‚Äôs CHEERS requirement for clear uncertainty reporting (HE 11, Section 6). Policymakers must also consider **equity** (e.g., access for low-income patients, HE 6, Section 2) and **budget impact** (HE 12, Section 6).

**c. Plotting the Tornado Diagram**  
- **Description**: A tornado diagram visualizes the impact of drug cost variation on the ICER, showing the range of ICERs relative to the base case (HE 10, Section 8; HE 11, Section 6).  
- **Data**:  
  - Base-case ICER: RM 80,000.  
  - Cost variation: RM 48,000 (ICER = RM 64,000), RM 72,000 (ICER = RM 96,000).  
- **Axes**:  
  - X-axis: ICER (RM per QALY, ranging from 60,000 to 100,000).  
  - Y-axis: Parameter (‚ÄúDrug Cost‚Äù).  
- **Instructions for Plotting**:  
  1. Draw a horizontal bar graph with the x-axis labeled ‚ÄúICER (RM per QALY)‚Äù (60,000 to 100,000) and the y-axis labeled ‚ÄúParameter.‚Äù  
  2. Plot a single horizontal bar for ‚ÄúDrug Cost,‚Äù extending from RM 64,000 (left) to RM 96,000 (right).  
  3. Mark the base-case ICER (RM 80,000) with a vertical line through the bar.  
  4. Label the bar ends with RM 48,000 (ICER = 64,000) and RM 72,000 (ICER = 96,000).  
  5. Add a dashed vertical line at RM 100,000 to indicate the WTP threshold.  
  6. Title the graph ‚ÄúTornado Diagram: Sensitivity of ICER to Drug Cost Variation.‚Äù  
- **Explanation**: The tornado diagram shows that drug cost variation significantly impacts the ICER, with a 20% cost decrease lowering the ICER by 20% and a 20% increase raising it by 20%, yet all values remain cost-effective (HE 10, Section 8). This visualization, per **HE 11**‚Äôs CHEERS item 20, ensures **transparency** in uncertainty reporting, aiding **MaHTAS** decisions (HE 11, Section 6; HE 12, Section 10).

#### Question 5: DRG Costing for Hospital Admissions (HE 12)

**Task**:  
a. Verify the **base rate** using the provided formula.  
b. Calculate the **cost per case** for Appendectomy and Stroke DRGs.  
c. Plot a **bar graph** comparing the costs of the two DRG groups, labeling the groups and costs.

**Answer**:

**a. Verify the Base Rate**  
- **Data**: Hospital Pool (HP_t) = RM 40,000,000, Cases (Cases_h,t-1) = 10,000, Base Rate (BR_t) = RM 4,000.  
- **Formula**:  
  $$\text{BR}_t = \frac{\text{HP}_t}{\text{Cases}_{h,t-1}}$$  
- **Calculation**:  
  - $$\text{BR}_t = \frac{40,000,000}{10,000} = 4,000$$  
  - **Verification**: The base rate of RM 4,000 is correct, as it matches the provided value, aligning with **HE 12**‚Äôs DRG costing methodology (HE 12, Section 7).

**b. Calculate Cost per Case for Appendectomy and Stroke DRGs**  
- **Data**: Base Rate = RM 4,000, Appendectomy Cost Weight = 0.85, Stroke Cost Weight = 1.7.  
- **Formula**: Cost per Case = Base Rate √ó Cost Weight  
- **Calculation for Appendectomy**:  
  - $$4,000 \times 0.85 = 3,400$$  
  - **Cost per Case**: RM 3,400.  
- **Calculation for Stroke**:  
  - $$4,000 \times 1.7 = 6,800$$  
  - **Cost per Case**: RM 6,800.  
- **Explanation**: The Stroke DRG is more costly due to its higher resource intensity (cost weight = 1.7 vs. 0.85), reflecting **HE 12**‚Äôs emphasis on DRG‚Äôs ability to standardize costs for clinically similar groups (HE 12, Section 7). This supports Malaysia‚Äôs **casemix system** for hospital budgeting and **MaHTAS** evaluations, though **IT infrastructure** challenges limit full implementation (HE 12, Section 7).

**c. Plotting the Bar Graph**  
- **Description**: The bar graph compares the costs of Appendectomy (RM 3,400) and Stroke (RM 6,800) DRGs, illustrating resource intensity differences (HE 12, Section 7).  
- **Axes**:  
  - X-axis: DRG Groups (‚ÄúAppendectomy,‚Äù ‚ÄúStroke‚Äù).  
  - Y-axis: Cost per Case (RM, ranging from 0 to 8,000).  
- **Instructions for Plotting**:  
  1. Draw a bar graph with the x-axis labeled ‚ÄúDRG Groups‚Äù and the y-axis labeled ‚ÄúCost per Case (RM).‚Äù  
  2. Create two bars:  
     - ‚ÄúAppendectomy‚Äù at RM 3,400.  
     - ‚ÄúStroke‚Äù at RM 6,800.  
  3. Label each bar with its cost value (e.g., ‚ÄúRM 3,400,‚Äù ‚ÄúRM 6,800‚Äù).  
  4. Title the graph ‚ÄúDRG Cost Comparison: Appendectomy vs. Stroke.‚Äù  
- **Explanation**: The bar graph highlights the higher cost of Stroke due to greater resource use, supporting **DRG‚Äôs scalability** for hospital financing (HE 12, Section 7). This visualization aids **MaHTAS** in budgeting and aligns with **HE 4**‚Äôs focus on transparent financing (HE 4, Section 9).


#### Question 6: Supply and Demand for Influenza Vaccines (HE 1, HE 2, HE 6, HE 7)

**Explanation**:  
This question draws on **HE 2**‚Äôs concepts of **supply and demand** and **price elasticity** (Section 3), **HE 1**‚Äôs discussion of **market failures** (e.g., under-consumption of preventive care, Section 2), **HE 6**‚Äôs focus on **equity** and **social determinants** (Section 2), and **HE 7**‚Äôs emphasis on **government interventions** like subsidies and price controls (Section 2). The tasks require students to visualize market dynamics through graphs, calculate changes in demand, and analyze policy impacts, aligning with Malaysia‚Äôs **UHC** goals to improve access for vulnerable groups like the elderly. The **price ceiling** analysis tests understanding of market distortions and equity implications, critical for Malaysia‚Äôs high OOP context (31.5% of THE, HE 4, Section 9).

**Answer**:

**a. Draw and Label Initial Supply and Demand Curves (5 marks)**  
- **Description**: The initial supply and demand curves represent the market for quadrivalent influenza vaccines (QIV) without intervention, with an equilibrium price of RM 150 and quantity of 250,000 doses (HE 2, Section 3).  
- **Axes**:  
  - X-axis: Quantity (doses, ranging from 0 to 800,000).  
  - Y-axis: Price (RM, ranging from 0 to 200).  
- **Instructions for Plotting**:  
  1. Draw a Cartesian plane with the x-axis labeled ‚ÄúQuantity (Doses)‚Äù and the y-axis labeled ‚ÄúPrice (RM).‚Äù  
  2. Plot the **demand curve (D1)** as a downward-sloping line, intersecting the **supply curve (S)** at the equilibrium point (250,000 doses, RM 150).  
  3. Plot the **supply curve (S)** as an upward-sloping line, starting from a low quantity at a low price (e.g., 50,000 doses at RM 50) to a high quantity at a high price (e.g., 600,000 doses at RM 200).  
  4. Mark the equilibrium point at (250,000, 150) and label it ‚ÄúE1.‚Äù  
  5. Label the curves ‚ÄúD1‚Äù (initial demand) and ‚ÄúS‚Äù (supply), and title the graph ‚ÄúInitial Market for QIV.‚Äù  
- **Explanation**: The equilibrium at (250,000, RM 150) reflects the market without intervention, where supply equals demand (HE 2, Section 3). This indicates under-consumption of vaccines, a **market failure** due to **externalities** (e.g., herd immunity benefits not captured, HE 1, Section 2), particularly affecting low-income elderly who cannot afford RM 150 doses.

**b. Draw and Label New Curves After Full Subsidy (5 marks)**  
- **Description**: A full subsidy reduces the price to RM 0, shifting the demand curve rightward to a new equilibrium quantity of 700,000 doses, with the supply curve unchanged (HE 2, Section 3; HE 7, Section 2).  
- **Axes**: Same as part (a): X-axis (Quantity, 0 to 800,000), Y-axis (Price, 0 to 200).  
- **Instructions for Plotting**:  
  1. Use the same Cartesian plane from part (a), retaining the original supply curve (S).  
  2. Plot a new **demand curve (D2)**, shifted rightward, intersecting the supply curve at (700,000 doses, RM 0).  
  3. Mark the new equilibrium point at (700,000, 0) and label it ‚ÄúE2.‚Äù  
  4. Label the new demand curve ‚ÄúD2‚Äù (post-subsidy demand), and update the title to ‚ÄúMarket for QIV with Full Subsidy.‚Äù  
  5. Indicate the shift from D1 to D2 with an arrow to show increased demand due to the subsidy.  
- **Explanation**: The subsidy eliminates the price barrier, increasing demand from 250,000 to 700,000 doses, reflecting a rightward demand curve shift (HE 2, Section 3). This aligns with **HE 7**‚Äôs government intervention to address **market failures** by promoting preventive care access, supporting **UHC** goals (HE 7, Section 6).

**c. Calculate Change in Quantity Demanded and Impact on Private Providers (5 marks)**  
- **Calculation**:  
  - Initial quantity demanded: 250,000 doses (at RM 150).  
  - New quantity demanded: 700,000 doses (at RM 0 with subsidy).  
  - Change in quantity demanded = 700,000 - 250,000 = **450,000 doses**.  
- **Impact on Private Providers**:  
  - **Explanation**: Without the subsidy, private providers sell 250,000 doses at RM 150, generating revenue of RM 150 √ó 250,000 = RM 37,500,000 (HE 2, Section 3). With a full subsidy, the MOH covers the cost, increasing demand to 700,000 doses, potentially supplied by private providers at a negotiated price (e.g., RM 150, costing MOH RM 150 √ó 700,000 = RM 105,000,000). However, private providers selling at RM 150 without subsidy face reduced demand, as patients opt for subsidized doses, leading to revenue loss (HE 7, Section 2). This may push providers to participate in the MOH program or exit the market, impacting supply dynamics (HE 3, Section 5). The subsidy enhances **equity** by improving access for low-income elderly, aligning with **HE 6**‚Äôs focus on reducing **health inequities** (HE 6, Section 2).

**d. Analyze Price Ceiling Effects on Supply, Demand, and Elderly Access (10 marks)**  
- **Analysis**:  
  - **Price Ceiling (RM 70)**: Setting a price ceiling below the equilibrium price (RM 150) creates a market distortion (HE 2, Section 3; HE 7, Section 2).  
  - **Effect on Supply**: At RM 70, suppliers are less willing to provide vaccines due to lower profitability, reducing supply (e.g., to ~100,000 doses, assuming a supply curve point). This leads to a **shortage**, as quantity supplied is less than quantity demanded (HE 2, Section 3).  
  - **Effect on Demand**: At RM 70, demand increases (e.g., to ~400,000 doses, assuming a demand curve point), as the lower price makes vaccines more affordable, but the shortage limits actual purchases (HE 2, Section 3).  
  - **Effect on Elderly Access**: The price ceiling improves affordability for low-income elderly, aligning with **equity** goals (HE 6, Section 2), but the shortage restricts access, particularly for those without public sector access, exacerbating **health inequities** (HE 6, Section 9). Rural elderly face additional barriers due to **social determinants** like distance to providers (HE 6, Section 2).  
  - **Policy Implications**: The shortage may lead to black markets or long queues, undermining **UHC** (HE 7, Section 6). A better approach is a targeted subsidy via **Peka B40**, ensuring access without distorting supply (HE 4, Section 9; HE 5, Section 9).  
- **Explanation**: The price ceiling, while intended to enhance **equity**, creates a **market failure** by reducing supply, limiting vaccine availability (HE 1, Section 2). This contradicts **UHC** goals, as shortages disproportionately affect low-income elderly reliant on private providers (HE 6, Section 2). Malaysia‚Äôs high OOP reliance (31.5% of THE, HE 4, Section 9) underscores the need for subsidies over price controls to ensure equitable access without market distortions (HE 7, Section 2).

**Graph for Part (d) - Optional Visualization for Analysis**:  
- **Description**: To illustrate the price ceiling‚Äôs effects, a graph can show the supply and demand curves with the ceiling at RM 70.  
- **Instructions**:  
  1. Use the initial graph from part (a).  
  2. Draw a horizontal line at RM 70, labeled ‚ÄúPrice Ceiling.‚Äù  
  3. Mark the quantity demanded (~400,000 doses) and quantity supplied (~100,000 doses) at RM 70, indicating the shortage (difference between demand and supply).  
  4. Label the shortage area and title the graph ‚ÄúPrice Ceiling Effects on QIV Market.‚Äù  
- **Explanation**: The graph highlights the shortage caused by the price ceiling, reinforcing the analysis of reduced supply and limited access (HE 2, Section 3).
---

### Structured Case Study Questions (HE 1‚ÄìHE 12)

These questions require students to analyze complex scenarios, providing **critical analysis** and **policy recommendations** based on health economics principles from **HE 1‚ÄìHE 12**. Each case includes **sub-questions** to structure responses, testing **conceptual understanding**, **application**, and **synthesis**.

#### Case Study 1: Evaluating a New Hepatitis C Drug for Malaysia‚Äôs Public Health System (HE 9, HE 10, HE 11, HE 12)
**Scenario**: Malaysia‚Äôs Ministry of Health (MOH) is considering adopting a new Hepatitis C drug for its public health system. The drug costs RM 80,000 per patient annually, yielding 3.0 Quality-Adjusted Life Years (QALYs), compared to standard care at RM 30,000 per patient annually, yielding 2.2 QALYs. The target population is 50,000 patients. The study reporting these results omits details on the discount rate and utility valuation method but includes a probabilistic sensitivity analysis. Malaysia‚Äôs Willingness-to-Pay (WTP) threshold is RM 100,000 per QALY, and the MOH budget is constrained.

- **Sub-Questions**:  
  a. Calculate the **Incremental Cost-Effectiveness Ratio (ICER)** and determine if the drug is cost-effective.  
  b. Appraise the study‚Äôs reporting quality using the **CHEERS 2022 checklist** for items 8 (Perspective), 10 (Discount Rate), and 13 (Valuation of Outcomes), using the coding system (‚úÖ, üü°, ‚ùå).  
  c. Discuss how the reporting gaps affect the study‚Äôs **policy relevance** for **MaHTAS**.  
  d. Recommend whether **MaHTAS** should adopt the drug, considering **budget impact**, **equity**, and **feasibility**, and propose how to address reporting gaps.

#### Case Study 2: Prioritizing Cervical Cancer Screening Programs in Rural Malaysia (HE 6, HE 10, HE 12)
**Scenario**: The MOH is evaluating two cervical cancer screening programs for rural Malaysian women: **Program A (HPV Self-Sampling)** costs RM 100 per person, yields 0.05 QALYs, and targets 500,000 women annually; **Program B (Clinic-Based Pap Smear)** costs RM 150 per person, yields 0.06 QALYs, and targets 300,000 women. Both use a health system perspective, a 5-year horizon, and a 3% discount rate. Malaysia‚Äôs WTP threshold is RM 120,000 per QALY. Rural areas face access challenges, and equity is a priority.

- **Sub-Questions**:  
  a. Calculate the **ICER** for each program compared to no screening (0 QALYs, RM 0 cost) and determine cost-effectiveness.  
  b. Apply **Multi-Criteria Decision Analysis (MCDA)** to compare the programs, scoring **cost-effectiveness**, **equity**, and **feasibility** (use ‚úÖ Strong, ‚ö†Ô∏è Moderate, ‚ùå Weak).  
  c. Discuss how **social determinants of health** (e.g., rural access) influence the decision.  
  d. Recommend which program to fund, justifying with **MCDA** and **equity** considerations, and propose implementation strategies.

#### Case Study 3: Financing a National Diabetes Management Program (HE 4, HE 5, HE 10, HE 12)
**Scenario**: Malaysia is designing a national diabetes management program to reduce complications, funded through **Social Health Insurance (SHI)** or **Out-of-Pocket (OOP)** payments. The program costs RM 200 million annually, targeting 1 million patients, with an ICER of RM 90,000 per QALY (health system perspective, 10-year horizon, 3% discount rate). Without the program, complications cost RM 50 million annually. Malaysia‚Äôs WTP threshold is RM 100,000 per QALY, but high OOP reliance (31.5% of THE) raises equity concerns.

- **Sub-Questions**:  
  a. Calculate the **net budget impact** of the program compared to treating complications.  
  b. Evaluate the impact of **SHI** vs. **OOP financing** on **equity** and **financial protection**.  
  c. Discuss how **market failures** (e.g., moral hazard, provider-induced demand) might affect program costs.  
  d. Recommend a financing strategy, justifying with **equity**, **budget impact**, and **UHC** goals.

---

### Complete Answer Guide for Structured Case Study Questions

Below is a detailed answer guide for each case study question, including **calculations**, **analyses**, **policy recommendations**, and cross-references to **HE 1‚ÄìHE 12**, with a focus on Malaysia‚Äôs healthcare context and **UHC** goals.

#### Case Study 1: Evaluating a New Hepatitis C Drug for Malaysia‚Äôs Public Health System (HE 9, HE 10, HE 11, HE 12)

**Sub-Questions**:  
a. Calculate the **ICER** and determine if the drug is cost-effective.  
b. Appraise the study‚Äôs reporting quality using **CHEERS 2022** for items 8, 10, and 13.  
c. Discuss how reporting gaps affect **policy relevance** for **MaHTAS**.  
d. Recommend whether **MaHTAS** should adopt the drug, addressing reporting gaps.

**Answer**:

**a. Calculate the ICER and Determine Cost-Effectiveness**  
- **Data**:  
  - New drug: Cost = RM 80,000, QALYs = 3.0  
  - Standard care: Cost = RM 30,000, QALYs = 2.2  
  - WTP threshold: RM 100,000 per QALY (HE 12, Section 4).  
- **Formula**:  
  $$\text{ICER} = \frac{\text{Cost}_{\text{new}} - \text{Cost}_{\text{comparator}}}{\text{Effect}_{\text{new}} - \text{Effect}_{\text{comparator}}}$$  
- **Calculation**:  
  - Incremental cost = RM 80,000 - RM 30,000 = RM 50,000  
  - Incremental QALYs = 3.0 - 2.2 = 0.8 QALYs  
  - $$\text{ICER} = \frac{50,000}{0.8} = 62,500 \, \text{RM per QALY}$$  
- **Cost-Effectiveness**: The ICER of RM 62,500 per QALY is **below** the WTP threshold of RM 100,000, indicating the drug is **cost-effective** (HE 9, Section 4; HE 10, Section 7; HE 12, Section 4).  

**b. Appraise Reporting Quality Using CHEERS 2022**  
- **CHEERS Items and Coding (HE 11, Section 6)**:  
  - **Item 8: Perspective**: ‚úÖ Clearly reported (health system perspective, assumed based on MOH context).  
  - **Item 10: Discount Rate**: ‚ùå Not reported (study omits discount rate details).  
  - **Item 13: Valuation of Outcomes**: üü° Mentioned but incomplete (QALYs reported, but utility valuation method, e.g., EQ-5D, is not specified).  
- **Explanation**: The study clearly states the health system perspective, aligning with **MaHTAS** requirements (HE 11, Section 6). However, omitting the discount rate undermines transparency, as stakeholders cannot verify how future costs/QALYs were adjusted (HE 10, Section 6). Incomplete utility valuation details reduce QALY credibility, as per **CHEERS 2022** requirements (HE 11, Section 9).

**c. Impact of Reporting Gaps on Policy Relevance for MaHTAS**  
- **Discussion**: The missing discount rate (Item 10) and incomplete utility valuation (Item 13) reduce the study‚Äôs **policy relevance** for **MaHTAS**, as they hinder **reproducibility** and **trust** (HE 11, Sections 3, 9). Without a discount rate, policymakers cannot assess whether future costs/QALYs align with Malaysia‚Äôs 3% standard, potentially overvaluing benefits (HE 10, Section 6). Incomplete utility details obscure QALY validity, critical for **CUA** in **HTA** (HE 9, Section 4). These gaps, per **HE 11**‚Äôs CHEERS checklist, limit **MaHTAS**‚Äôs ability to make evidence-based decisions, especially given Malaysia‚Äôs budget constraints (2021 THE: RM 78.2 billion, HE 4, Section 9). The gaps also raise **equity** concerns, as unclear QALYs may not reflect benefits for low-income patients, aligning with **HE 6**‚Äôs focus on addressing **health inequities** (HE 6, Section 2).

**d. Policy Recommendation and Addressing Reporting Gaps**  
- **Recommendation**: **MaHTAS** should **conditionally adopt** the Hepatitis C drug, given its cost-effective ICER (RM 62,500 < RM 100,000), but require a revised study with improved reporting to confirm findings (HE 12, Section 10). The **budget impact** (RM 80,000 √ó 50,000 = RM 4 billion annually) is significant, straining fiscal space, so phased implementation targeting high-risk groups (e.g., rural patients) is advised to enhance **equity** (HE 12, Section 6; HE 6, Section 2). **Feasibility** requires assessing drug supply chains and clinician training (HE 12, Section 5).  
- **Addressing Gaps**: Request authors to:  
  1. Specify the **discount rate** (e.g., 3%, per MaHTAS norms, HE 10, Section 6) to ensure transparency (CHEERS Item 10, HE 11, Section 6).  
  2. Detail **utility valuation** methods (e.g., EQ-5D with Malaysian tariffs) to validate QALYs (CHEERS Item 13, HE 11, Section 6).  
  3. Conduct additional **sensitivity analyses** on cost and utility parameters to enhance robustness (HE 10, Section 8).  
- **Justification**: Conditional adoption balances **cost-effectiveness** with **budget constraints** and **equity**, aligning with **UHC** goals (HE 5, Section 9; HE 12, Section 10). Improved reporting ensures **MaHTAS** can trust the findings, supporting **evidence-based policy** (HE 11, Section 10).

#### Case Study 2: Prioritizing Cervical Cancer Screening Programs in Rural Malaysia (HE 6, HE 10, HE 12)

**Sub-Questions**:  
a. Calculate the **ICER** for each program compared to no screening and determine cost-effectiveness.  
b. Apply **MCDA** to compare programs, scoring **cost-effectiveness**, **equity**, and **feasibility**.  
c. Discuss how **social determinants** influence the decision.  
d. Recommend which program to fund, with implementation strategies.

**Answer**:

**a. Calculate ICER and Determine Cost-Effectiveness**  
- **Data**:  
  - Program A (HPV Self-Sampling): Cost = RM 100 per person, QALYs = 0.05, Population = 500,000.  
  - Program B (Clinic-Based Pap Smear): Cost = RM 150 per person, QALYs = 0.06, Population = 300,000.  
  - No screening: Cost = RM 0, QALYs = 0.  
  - WTP threshold: RM 120,000 per QALY (HE 12, Section 4).  
- **Formula**:  
  $$\text{ICER} = \frac{\text{Cost}_{\text{new}} - \text{Cost}_{\text{comparator}}}{\text{Effect}_{\text{new}} - \text{Effect}_{\text{comparator}}}$$  
- **Calculation for Program A**:  
  - Incremental cost = RM 100 - RM 0 = RM 100  
  - Incremental QALYs = 0.05 - 0 = 0.05  
  - $$\text{ICER} = \frac{100}{0.05} = 2,000 \, \text{RM per QALY}$$  
- **Calculation for Program B**:  
  - Incremental cost = RM 150 - RM 0 = RM 150  
  - Incremental QALYs = 0.06 - 0 = 0.06  
  - $$\text{ICER} = \frac{150}{0.06} = 2,500 \, \text{RM per QALY}$$  
- **Cost-Effectiveness**: Both programs are **highly cost-effective**, as their ICERs (RM 2,000 and RM 2,500 per QALY) are far below the WTP threshold of RM 120,000 (HE 9, Section 4; HE 10, Section 7; HE 12, Section 4).  

**b. Apply MCDA to Compare Programs**  
- **MCDA Scoring (HE 12, Section 10)**:  
  | **Criterion** | **Program A (HPV)** | **Program B (Pap Smear)** |  
  |--------------|--------------------|-------------------------|  
  | **Cost-Effectiveness** | ‚úÖ Strong (ICER = RM 2,000) | ‚úÖ Strong (ICER = RM 2,500) |  
  | **Equity** | ‚úÖ Strong (self-sampling improves rural access) | ‚ö†Ô∏è Moderate (clinic-based, limited by access) |  
  | **Feasibility** | ‚úÖ Strong (mobile deployment feasible) | ‚ö†Ô∏è Moderate (requires clinic infrastructure) |  
  | **Total Score** | High | Moderate |  
- **Explanation**: Both programs are cost-effective, but Program A scores higher in **equity** due to self-sampling‚Äôs accessibility in rural areas, addressing **Inverse Care Law** issues (HE 6, Section 2). Program A‚Äôs **feasibility** is stronger, as mobile deployment requires less infrastructure than clinic expansion (HE 12, Section 5). Program B‚Äôs higher ICER and reliance on clinics reduce its equity and feasibility (HE 10, Section 10).

**c. Influence of Social Determinants**  
- **Discussion**: **Social determinants of health** (e.g., rural access, poverty, education) significantly influence the decision (HE 6, Section 9). Rural Malaysian women face barriers like distance to clinics and low health literacy, exacerbating **health inequities** (e.g., higher cervical cancer rates, HE 6, Section 2). Program A‚Äôs self-sampling approach mitigates these by enabling home-based testing, improving access and equity, while Program B‚Äôs clinic requirement limits reach, aligning with **HE 6**‚Äôs **Inverse Care Law** (HE 6, Section 2). **HE 10**‚Äôs emphasis on context-specific outcomes (e.g., QALYs reflecting rural needs) supports Program A‚Äôs relevance for **UHC** goals (HE 10, Section 5; HE 5, Section 9).

**d. Recommendation and Implementation Strategies**  
- **Recommendation**: Fund **Program A (HPV Self-Sampling)** due to its **high MCDA score**, **strong equity benefits**, and **feasibility** (HE 12, Section 10). Its ICER (RM 2,000) is highly cost-effective, and its budget impact (RM 100 √ó 500,000 = RM 50 million) is manageable compared to Program B (RM 150 √ó 300,000 = RM 45 million), especially given Program A‚Äôs larger reach (HE 12, Section 6).  
- **Implementation Strategies**:  
  1. Deploy **mobile health units** to distribute self-sampling kits, addressing rural access barriers (HE 6, Section 9).  
  2. Partner with **community health workers** to educate women, improving uptake and addressing low health literacy (HE 6, Section 2).  
  3. Use **DRG/case-mix costing** to standardize screening costs for budgeting, leveraging Malaysia‚Äôs UNU-CBG Grouper (HE 12, Section 7).  
  4. Integrate with **Peka B40** to subsidize costs, reducing OOP burdens (31.5% of THE, HE 4, Section 9).  
- **Justification**: Program A aligns with **UHC** and **equity** goals, addressing rural disparities and ensuring cost-effective, scalable screening (HE 5, Section 9; HE 12, Section 10).

#### Case Study 3: Financing a National Diabetes Management Program (HE 4, HE 5, HE 10, HE 12)

**Sub-Questions**:  
a. Calculate the **net budget impact** of the program compared to treating complications.  
b. Evaluate **SHI** vs. **OOP financing** on **equity** and **financial protection**.  
c. Discuss how **market failures** affect program costs.  
d. Recommend a financing strategy, justifying with **equity**, **budget impact**, and **UHC** goals.

**Answer**:

**a. Calculate Net Budget Impact**  
- **Data**:  
  - Program cost: RM 200 million annually, 1 million patients.  
  - Complication treatment cost: RM 50 million annually.  
- **Calculation**:  
  - Net Budget Impact = Program Cost - Complication Cost  
  - $$200,000,000 - 50,000,000 = 150,000,000$$  
  - **Net Budget Impact**: Additional cost of RM 150,000,000.  
- **Explanation**: The program incurs an additional RM 150 million compared to treating complications, reflecting a significant **budget impact** despite its cost-effective ICER (RM 90,000 < RM 100,000, HE 12, Section 6). This aligns with **HE 12**‚Äôs emphasis on assessing **fiscal space** (HE 12, Section 6).

**b. Evaluate SHI vs. OOP Financing**  
- **SHI**:  
  - **Equity**: Enhances equity by spreading costs across a mandatory risk pool, reducing financial barriers for low-income patients (HE 5, Section 5).  
  - **Financial Protection**: Protects against catastrophic health expenditures, critical given Malaysia‚Äôs 31.5% OOP reliance (HE 4, Section 9).  
- **OOP**:  
  - **Equity**: Exacerbates inequities, as low-income patients face financial burdens, worsening access disparities (HE 6, Section 2).  
  - **Financial Protection**: Increases risk of financial hardship, undermining **UHC** goals (HE 5, Section 9).  
- **Explanation**: **SHI** aligns with **HE 5**‚Äôs focus on **risk pooling** for equitable access, while **OOP** contradicts **HE 6**‚Äôs emphasis on reducing **health inequities** (HE 5, Section 5; HE 6, Section 2).

**c. Impact of Market Failures**  
- **Discussion**: **Market failures** like **moral hazard** and **provider-induced demand** can inflate program costs (HE 3, Section 5; HE 7, Section 2). **Moral hazard** may lead to overuse of subsidized services (e.g., unnecessary tests) under SHI, increasing costs (HE 5, Section 5). **Provider-induced demand** could result in over-prescription of treatments by private providers, especially in Malaysia‚Äôs dual system (HE 3, Section 5). These align with **HE 7**‚Äôs call for government regulation (e.g., **separation of prescribing and dispensing**) to mitigate cost escalation (HE 7, Section 2). Robust **costing** (e.g., DRG, HE 12, Section 7) and **sensitivity analysis** (HE 10, Section 8) are needed to account for these risks.

**d. Financing Strategy Recommendation**  
- **Recommendation**: Adopt **SHI** financing for the diabetes program to enhance **equity** and **financial protection**, aligning with **UHC** goals (HE 5, Section 9; HE 12, Section 10). The **net budget impact** (RM 150 million) is significant but justifiable given the cost-effective ICER (RM 90,000), which supports **MaHTAS** adoption (HE 12, Section 4).  
- **Implementation Strategies**:  
  1. Implement **SHI** through mandatory contributions, leveraging **risk pooling** to spread costs (HE 5, Section 5).  
  2. Use **DRG/case-mix costing** to standardize program costs, ensuring scalability (HE 12, Section 7).  
  3. Introduce **gatekeeping** to mitigate **moral hazard** and **provider-induced demand** (HE 5, Section 8; HE 7, Section 2).  
  4. Target **high-risk groups** (e.g., rural, low-income) to address **equity**, integrating with **Peka B40** (HE 6, Section 2).  
- **Justification**: **SHI** reduces OOP burdens, addressing Malaysia‚Äôs high OOP reliance (HE 4, Section 9) and promoting **equity** (HE 6, Section 2). The program‚Äôs cost-effectiveness supports **UHC**, while regulatory measures ensure cost control (HE 12, Section 10).

---

### Short-Essay Questions (HE 1‚ÄìHE 12)

These questions require students to apply health economics concepts to **practical scenarios**, demonstrating **conceptual understanding** and **problem-solving skills**. Answers should be concise (150‚Äì200 words) and address Malaysia-specific contexts where relevant.

1. **Market Failures in Malaysia‚Äôs Dual Healthcare System (HE 1, HE 3, HE 7)**  
   Malaysia‚Äôs dual public-private healthcare system faces issues like provider-induced demand and information asymmetry. Discuss how these **market failures** affect healthcare costs and access, and propose a government intervention to address one of these issues, justifying its alignment with **UHC** goals.

2. **Equity Implications of High OOP Payments (HE 4, HE 6)**  
   Malaysia‚Äôs high out-of-pocket (OOP) payments (31.5% of THE in 2021) exacerbate health inequities. Explain how OOP reliance impacts **equity**, particularly for rural populations, and propose a financing strategy to mitigate these effects, referencing **social determinants of health**.

3. **Role of Social Health Insurance in Financial Protection (HE 5, HE 6)**  
   Social Health Insurance (SHI) is proposed to reduce Malaysia‚Äôs OOP reliance. Discuss how **SHI** enhances **financial protection** and **equity**, and address potential challenges (e.g., moral hazard) in its implementation, suggesting mitigation strategies.

4. **Importance of Perspective in Economic Evaluations (HE 9, HE 10)**  
   The choice of perspective (e.g., societal vs. health system) significantly affects economic evaluation outcomes. Using a Malaysian example (e.g., a new diabetes drug), explain how perspective influences **cost-effectiveness** conclusions and why aligning perspective with policy goals is critical.

5. **CHEERS 2022 for Transparent Reporting (HE 11)**  
   A study evaluating a new hypertension drug in Malaysia omits perspective and sensitivity analysis details. Using **CHEERS 2022**, discuss how these reporting gaps affect its **policy relevance** for **MaHTAS**, and propose improvements to enhance transparency.

6. **Applying MCDA for Policy Decisions (HE 12)**  
   Malaysia is considering two interventions: HPV self-sampling and stroke rehabilitation. Discuss how **Multi-Criteria Decision Analysis (MCDA)** can balance **cost-effectiveness**, **equity**, and **feasibility**, and recommend one intervention, justifying with Malaysia-specific considerations.

---

### Complete Answer Guide for Short-Essay Questions

Below is a detailed answer guide for each short-essay question, including **explanations** and **model answers** (150‚Äì200 words each), with cross-references to **HE 1‚ÄìHE 12** and integration of Malaysia‚Äôs healthcare context (e.g., 2021 THE: RM 78.2 billion, 5.1% GDP; OOP: 31.5% of THE). Each answer demonstrates **conceptual understanding**, **problem-solving skills**, and **policy relevance**, aligning with **UHC** and **health equity** goals.

#### Question 1: Market Failures in Malaysia‚Äôs Dual Healthcare System (HE 1, HE 3, HE 7)

**Question**: Malaysia‚Äôs dual public-private healthcare system faces issues like provider-induced demand and information asymmetry. Discuss how these **market failures** affect healthcare costs and access, and propose a government intervention to address one of these issues, justifying its alignment with **UHC** goals.

**Explanation**:  
**Market failures** (e.g., provider-induced demand, information asymmetry) disrupt efficient resource allocation, inflating costs and limiting access, as introduced in **HE 1** (Section 2) and detailed in **HE 3** (Section 5). **Provider-induced demand** occurs when providers encourage unnecessary treatments for profit, common in Malaysia‚Äôs private sector, while **information asymmetry** leaves patients unable to assess care quality, leading to over-treatment or under-treatment. These increase costs and exacerbate inequities, particularly for low-income groups. **HE 7** emphasizes government interventions like regulations to address such failures (Section 2). The proposed intervention should align with **UHC** goals (HE 7, Section 6) by improving access and affordability.

**Model Answer (150‚Äì200 words)**:  
Malaysia‚Äôs dual healthcare system faces **market failures** like **provider-induced demand** and **information asymmetry**, inflating costs and limiting access (HE 1, Section 2; HE 3, Section 5). **Provider-induced demand** in private hospitals drives unnecessary procedures, increasing costs (e.g., private sector‚Äôs 40% outpatient share, HE 3, Section 5), while **information asymmetry** leaves patients vulnerable to over-treatment, raising OOP expenses (31.5% of THE, HE 4, Section 9). This disproportionately affects low-income groups, worsening **health inequities** (HE 6, Section 2). A proposed government intervention is enforcing **separation of prescribing and dispensing** in private clinics, as piloted by Malaysia‚Äôs MOH (HE 7, Section 2). This regulation reduces providers‚Äô financial incentives to over-prescribe, lowering costs and improving care quality. By enhancing affordability and access, it aligns with **UHC** goals, ensuring equitable healthcare (HE 7, Section 6). Implementation requires stakeholder engagement and monitoring to ensure compliance, particularly in rural areas, addressing **social determinants** like access barriers (HE 6, Section 9). This intervention fosters a sustainable, equitable health system, supporting Malaysia‚Äôs **UHC** aspirations.

**Word Count**: 163

#### Question 2: Equity Implications of High OOP Payments (HE 4, HE 6)

**Question**: Malaysia‚Äôs high out-of-pocket (OOP) payments (31.5% of THE in 2021) exacerbate health inequities. Explain how OOP reliance impacts **equity**, particularly for rural populations, and propose a financing strategy to mitigate these effects, referencing **social determinants of health**.

**Explanation**:  
High OOP payments, as noted in **HE 4** (Section 9), create financial barriers, disproportionately affecting low-income and rural populations, leading to **health inequities** (HE 6, Section 2). **Social determinants** like poverty and lack of access to facilities exacerbate these disparities, as rural patients face higher travel costs and limited infrastructure (HE 6, Section 9). A financing strategy, such as **Social Health Insurance (SHI)** or increased public subsidies, can reduce OOP burdens, aligning with **UHC** goals (HE 4, Section 4). The proposal should address how **social determinants** influence access and suggest practical mitigation measures.

**Model Answer (150‚Äì200 words)**:  
Malaysia‚Äôs high OOP payments (31.5% of THE in 2021) exacerbate **health inequities**, particularly for rural populations, by creating financial barriers to care (HE 4, Section 9). Rural communities, facing **social determinants** like poverty and limited healthcare access, often forgo treatment due to high costs, worsening disparities (e.g., higher rural IMR, HE 6, Section 2). OOP reliance forces patients to cover expenses like consultations and medications, disproportionately burdening low-income households, aligning with the **Inverse Care Law** (HE 6, Section 2). A proposed financing strategy is implementing **Social Health Insurance (SHI)**, which pools risks and subsidizes care, reducing OOP costs (HE 4, Section 4). SHI would enhance **equity** by ensuring access for rural populations, addressing barriers like travel costs and low health literacy (HE 6, Section 9). Implementation requires mandatory contributions and government subsidies to cover low-income groups, integrated with **Peka B40** to target rural areas (HE 4, Section 9). This aligns with **UHC** goals, improving financial protection and equitable access across Malaysia‚Äôs diverse population.

**Word Count**: 158

#### Question 3: Role of Social Health Insurance in Financial Protection (HE 5, HE 6)

**Question**: Social Health Insurance (SHI) is proposed to reduce Malaysia‚Äôs OOP reliance. Discuss how **SHI** enhances **financial protection** and **equity**, and address potential challenges (e.g., moral hazard) in its implementation, suggesting mitigation strategies.

**Explanation**:  
**SHI**, as discussed in **HE 5** (Section 5), enhances **financial protection** by pooling risks across a population, reducing individual OOP costs. It promotes **equity** by ensuring access for low-income groups, addressing **social determinants** like poverty (HE 6, Section 2). However, **moral hazard**‚Äîoveruse of insured services‚Äîcan increase costs (HE 5, Section 5). Mitigation strategies, such as **gatekeeping** or co-payments, align with **HE 5**‚Äôs managed care principles (Section 8). The answer should highlight SHI‚Äôs benefits and propose practical solutions to challenges, referencing Malaysia‚Äôs context.

**Model Answer (150‚Äì200 words)**:  
**Social Health Insurance (SHI)** enhances **financial protection** by pooling risks, reducing Malaysia‚Äôs high OOP reliance (31.5% of THE, HE 4, Section 9), and ensuring access to care without catastrophic costs (HE 5, Section 5). By covering low-income groups, SHI promotes **equity**, addressing **social determinants** like poverty and rural access barriers, reducing disparities (e.g., rural-urban IMR gap, HE 6, Section 2). For example, SHI can subsidize diabetes care for **Peka B40** beneficiaries, improving access (HE 6, Section 3). However, **moral hazard**‚Äîwhere insured patients overuse services like consultations‚Äîcan inflate costs (HE 5, Section 5). Mitigation includes **gatekeeping** through primary care referrals and modest co-payments to deter unnecessary use, as seen in managed care systems (HE 5, Section 8). Implementation requires robust **National Health Accounts (NHAs)** to track funding and ensure transparency (HE 4, Section 9). Engaging stakeholders to design contribution rates ensures sustainability, aligning with **UHC** goals to provide equitable, affordable care across Malaysia‚Äôs diverse population (HE 5, Section 9).

**Word Count**: 160

#### Question 4: Importance of Perspective in Economic Evaluations (HE 9, HE 10)

**Question**: The choice of perspective (e.g., societal vs. health system) significantly affects economic evaluation outcomes. Using a Malaysian example (e.g., a new diabetes drug), explain how perspective influences **cost-effectiveness** conclusions and why aligning perspective with policy goals is critical.

**Explanation**:  
**Perspective** determines which costs and outcomes are included in economic evaluations, affecting **cost-effectiveness** conclusions (HE 9, Section 6; HE 10, Section 4). A **societal perspective** includes all costs (e.g., productivity losses), while a **health system perspective** focuses on direct medical costs, impacting the **ICER** (HE 10, Section 7). Aligning perspective with policy goals ensures relevance for stakeholders like **MaHTAS** (HE 9, Section 3). The answer should use a Malaysian example to illustrate perspective‚Äôs impact and justify alignment with policy objectives.

**Model Answer (150‚Äì200 words)**:  
The choice of **perspective** in economic evaluations significantly influences **cost-effectiveness** conclusions by determining included costs and outcomes (HE 9, Section 6; HE 10, Section 4). For a new diabetes drug in Malaysia, a **health system perspective** includes only direct medical costs (e.g., drug cost, hospitalizations), yielding a higher **ICER** (e.g., RM 90,000 per QALY) if costs are substantial, potentially deeming it not cost-effective (HE 10, Section 7). A **societal perspective**, including productivity losses from complications, may lower the ICER (e.g., RM 70,000 per QALY) by capturing broader benefits, making it cost-effective (HE 9, Section 6). Aligning perspective with policy goals is critical: **MaHTAS** prioritizes the health system perspective for budgeting, ensuring fiscal sustainability (HE 12, Section 10), while a societal perspective supports **UHC** by addressing **health inequities** for rural patients (HE 6, Section 2). Choosing the appropriate perspective ensures evaluations are relevant for **MaHTAS** or **Peka B40**, guiding evidence-based decisions that balance efficiency and equity in Malaysia‚Äôs resource-constrained system (2021 THE: RM 78.2 billion, HE 4, Section 9).

**Word Count**: 170

#### Question 5: CHEERS 2022 for Transparent Reporting (HE 11)

**Question**: A study evaluating a new hypertension drug in Malaysia omits perspective and sensitivity analysis details. Using **CHEERS 2022**, discuss how these reporting gaps affect its **policy relevance** for **MaHTAS**, and propose improvements to enhance transparency.

**Explanation**:  
**CHEERS 2022** ensures **transparent reporting** of economic evaluations, critical for **policy relevance** (HE 11, Section 4). Omitting perspective (Item 8) and sensitivity analysis (Item 20) undermines **reproducibility** and **trust**, as stakeholders cannot assess cost/outcome scope or result robustness (HE 11, Sections 6, 9). Improvements should address these gaps to align with **MaHTAS** requirements. The answer should discuss the impact of these gaps and propose specific **CHEERS** improvements, referencing Malaysia‚Äôs context.

**Model Answer (150‚Äì200 words)**:  
Omitting **perspective** (CHEERS Item 8) and **sensitivity analysis** (Item 20) in a study evaluating a new hypertension drug reduces its **policy relevance** for **MaHTAS** by undermining **transparency** and **reproducibility** (HE 11, Sections 4, 6). Without a stated perspective (e.g., health system), **MaHTAS** cannot determine which costs (e.g., medical vs. productivity losses) are included, making the **ICER** uninterpretable (HE 11, Section 9). Missing sensitivity analysis obscures result robustness, critical for assessing uncertainty in Malaysia‚Äôs budget-constrained system (2021 THE: RM 78.2 billion, HE 4, Section 9). These gaps limit trust, hindering adoption decisions (HE 11, Section 3). **Improvements** include: 1) Specifying a **health system perspective** to align with **MaHTAS** budgeting needs (HE 10, Section 4); 2) Conducting **one-way and probabilistic sensitivity analyses** on drug costs and QALYs to ensure robustness (HE 10, Section 8); 3) Reporting data sources (e.g., MOH tariffs) per **CHEERS Item 14** (HE 11, Section 6). These enhancements ensure **transparent reporting**, supporting **evidence-based policy** for **UHC** and **equity** in Malaysia (HE 6, Section 2).

**Word Count**: 165

#### Question 6: Applying MCDA for Policy Decisions (HE 12)

**Question**: Malaysia is considering two interventions: HPV self-sampling and stroke rehabilitation. Discuss how **Multi-Criteria Decision Analysis (MCDA)** can balance **cost-effectiveness**, **equity**, and **feasibility**, and recommend one intervention, justifying with Malaysia-specific considerations.

**Explanation**:  
**MCDA** integrates **cost-effectiveness**, **equity**, and **feasibility** to inform policy decisions, as emphasized in **HE 12** (Section 10). It scores and weights criteria to prioritize interventions, balancing economic and societal factors. In Malaysia‚Äôs context, **equity** (e.g., rural access) and **feasibility** (e.g., infrastructure) are critical, alongside **cost-effectiveness** (HE 6, Section 2; HE 12, Section 5). The recommendation should use **MCDA** to justify the choice, addressing Malaysia‚Äôs healthcare challenges.

**Model Answer (150‚Äì200 words)**:  
**Multi-Criteria Decision Analysis (MCDA)** balances **cost-effectiveness**, **equity**, and **feasibility** to prioritize interventions in Malaysia‚Äôs resource-constrained health system (HE 12, Section 10). For **HPV self-sampling** (ICER: RM 85,000, budget impact: RM 50 million) and **stroke rehabilitation** (ICER: RM 130,000, budget impact: RM 15 million), MCDA evaluates: 1) **Cost-effectiveness**: HPV self-sampling is stronger (ICER < RM 120,000 WTP threshold), while stroke rehabilitation exceeds it (HE 12, Section 5). 2) **Equity**: HPV self-sampling benefits rural women, addressing **Inverse Care Law** disparities (HE 6, Section 2). 3) **Feasibility**: HPV‚Äôs mobile deployment is more scalable than stroke rehabilitation‚Äôs specialized centers (HE 12, Section 5). **Recommendation**: Prioritize **HPV self-sampling** due to its high MCDA score, aligning with **UHC** by improving access for underserved women (HE 5, Section 9). **Justification**: Its cost-effective ICER, moderate budget impact, and equity benefits outweigh stroke rehabilitation‚Äôs lower feasibility and higher ICER. Implementation via **Peka B40** and mobile units ensures affordability and access, reducing Malaysia‚Äôs OOP reliance (31.5% of THE, HE 4, Section 9).

**Word Count**: 171

---

### Open-Ended Long Essay Questions (HE 1‚ÄìHE 12)

These questions require **in-depth analysis** to address complex healthcare challenges, encouraging **critical thinking**, **synthesis**, and **policy recommendations** with a focus on **Malaysia-specific** and **global applications**. Answers should be 500‚Äì600 words, integrating lecture content and practical scenarios.

1. **Addressing Market Failures and Equity in Malaysia‚Äôs Dual Healthcare System (HE 1, HE 3, HE 6, HE 7)**  
   Malaysia‚Äôs dual public-private healthcare system faces market failures such as provider-induced demand and information asymmetry, exacerbating health inequities. Analyze how these market failures impact healthcare costs and access, particularly for rural populations. Propose a comprehensive government intervention strategy to address these issues, drawing on global examples (e.g., UK‚Äôs NHS) and justifying its alignment with Malaysia‚Äôs **UHC** goals.

2. **Enhancing Financial Protection Through Health Financing Reforms (HE 4, HE 5, HE 6)**  
   High out-of-pocket (OOP) payments in Malaysia (31.5% of THE in 2021) hinder equitable access to healthcare. Evaluate the role of **Social Health Insurance (SHI)** in enhancing **financial protection** and reducing **health inequities**, comparing Malaysia‚Äôs approach to global models (e.g., Thailand‚Äôs UCS). Propose a financing reform strategy to mitigate OOP reliance, addressing challenges like moral hazard and ensuring alignment with **UHC** objectives.

3. **Applying Economic Evaluations for Non-Communicable Disease Interventions (HE 9, HE 10, HE 12)**  
   Non-communicable diseases (NCDs) like diabetes and hypertension are a growing burden in Malaysia. Discuss how **economic evaluations** (e.g., ICER, costing, modeling) can guide the adoption of NCD interventions, focusing on Malaysia-specific challenges (e.g., budget constraints, rural disparities). Propose a framework for prioritizing NCD interventions using **Multi-Criteria Decision Analysis (MCDA)**, drawing on global HTA practices (e.g., NICE).

4. **Ensuring Transparent and Policy-Relevant Economic Evaluations (HE 11, HE 12)**  
   Transparent reporting via **CHEERS 2022** is critical for policy-relevant economic evaluations in Malaysia‚Äôs health system. Analyze the challenges of ensuring transparency in evaluations for high-cost interventions (e.g., cancer therapies), focusing on common reporting gaps. Propose a framework for Malaysian researchers to align studies with **CHEERS 2022**, incorporating global HTA standards (e.g., HITAP, NICE) to enhance policy uptake.

---

### Complete Answer Guide for Open-Ended Long Essay Questions

Below is a detailed answer guide for each open-ended long essay question, including **explanations** and **model answers** (500‚Äì600 words each), with cross-references to **HE 1‚ÄìHE 12** and integration of Malaysia‚Äôs healthcare context (e.g., 2021 THE: RM 78.2 billion, 5.1% GDP; OOP: 31.5% of THE). Each answer provides **in-depth analysis**, **critical thinking**, **synthesis**, and **policy recommendations**, aligning with **UHC** and **health equity** goals.

#### Question 1: Addressing Market Failures and Equity in Malaysia‚Äôs Dual Healthcare System (HE 1, HE 3, HE 6, HE 7)

**Question**: Malaysia‚Äôs dual public-private healthcare system faces market failures such as provider-induced demand and information asymmetry, exacerbating health inequities. Analyze how these market failures impact healthcare costs and access, particularly for rural populations. Propose a comprehensive government intervention strategy to address these issues, drawing on global examples (e.g., UK‚Äôs NHS) and justifying its alignment with Malaysia‚Äôs **UHC** goals.

**Explanation**:  
Malaysia‚Äôs dual healthcare system, with a public sector serving 60% of outpatient visits and a private sector driving high OOP costs (HE 4, Section 9), is prone to **market failures** like **provider-induced demand** and **information asymmetry** (HE 1, Section 2; HE 3, Section 5). These increase costs and limit access, particularly for rural populations facing **social determinants** like poverty and distance to facilities (HE 6, Section 9). **HE 7** highlights government interventions (e.g., regulations, subsidies) to mitigate these failures (Section 2). The answer should analyze impacts, propose a strategy inspired by global models (e.g., UK‚Äôs NHS), and align with **UHC** goals (HE 7, Section 6).

**Model Answer (500‚Äì600 words)**:  
Malaysia‚Äôs dual public-private healthcare system, characterized by public subsidies and private growth, faces significant **market failures** that inflate costs and exacerbate **health inequities**, particularly for rural populations (HE 1, Section 2). **Provider-induced demand**, where private providers over-prescribe for profit, drives unnecessary treatments, contributing to high OOP payments (31.5% of THE in 2021, HE 4, Section 9; HE 3, Section 5). **Information asymmetry** leaves patients, especially in rural areas with low health literacy, unable to assess care quality, leading to over-treatment or under-treatment (HE 3, Section 5). These failures increase costs, with private facilities handling 40% of outpatient visits, and limit access for rural communities facing **social determinants** like poverty and distance to clinics, worsening disparities (e.g., higher rural IMR, HE 6, Section 2). The **Inverse Care Law** highlights that those needing care most‚Äîrural, low-income groups‚Äîreceive the least, undermining **equity** (HE 6, Section 2).

A comprehensive government intervention strategy is implementing a **nationwide separation of prescribing and dispensing** policy, expanding Malaysia‚Äôs pilot program (HE 7, Section 2). This regulation requires physicians to prescribe medications and pharmacists to dispense them, reducing financial incentives for over-prescription in private clinics. By decoupling profit motives, it lowers costs and improves care quality, addressing **provider-induced demand**. Drawing on the UK‚Äôs NHS, which uses strict prescribing guidelines to control costs, Malaysia can enforce standardized protocols through the MOH, ensuring transparency (HE 7, Section 7). To enhance rural access, mobile health units and telehealth services can deliver prescriptions, mitigating **information asymmetry** by providing patient education (HE 6, Section 9). Implementation requires:

1. **Regulatory Enforcement**: Mandate separation in private clinics, with penalties for non-compliance, as seen in the UK‚Äôs NHS (HE 7, Section 7).  
2. **Rural Infrastructure**: Deploy mobile pharmacies and telehealth to overcome access barriers, addressing **social determinants** (HE 6, Section 9).  
3. **Stakeholder Engagement**: Involve clinicians and pharmacists to ensure buy-in, reducing resistance (HE 7, Section 2).  
4. **Monitoring and Evaluation**: Use **National Health Accounts (NHAs)** to track cost reductions and access improvements, ensuring transparency (HE 4, Section 9).

This strategy aligns with **UHC** goals by improving affordability and access, particularly for rural populations (HE 7, Section 6). By reducing OOP burdens, it addresses **equity**, ensuring care reaches underserved groups (HE 6, Section 2). Global examples like Thailand‚Äôs UCS, which uses regulations to control private sector practices, demonstrate success in cost containment (HE 7, Section 7). Challenges include initial resistance from private providers and infrastructure costs, which can be mitigated through phased implementation and public subsidies. This intervention fosters a sustainable, equitable health system, supporting Malaysia‚Äôs **UHC** aspirations by balancing efficiency and fairness.

**Word Count**: 512

#### Question 2: Enhancing Financial Protection Through Health Financing Reforms (HE 4, HE 5, HE 6)

**Question**: High out-of-pocket (OOP) payments in Malaysia (31.5% of THE in 2021) hinder equitable access to healthcare. Evaluate the role of **Social Health Insurance (SHI)** in enhancing **financial protection** and reducing **health inequities**, comparing Malaysia‚Äôs approach to global models (e.g., Thailand‚Äôs UCS). Propose a financing reform strategy to mitigate OOP reliance, addressing challenges like moral hazard and ensuring alignment with **UHC** objectives.

**Explanation**:  
High OOP payments (HE 4, Section 9) create financial barriers, exacerbating **health inequities** for low-income and rural populations (HE 6, Section 2). **SHI**, discussed in **HE 5** (Section 5), pools risks to enhance **financial protection** and **equity**, but faces challenges like **moral hazard** (HE 5, Section 5). Thailand‚Äôs Universal Coverage Scheme (UCS) offers a global model for SHI success (HE 5, Section 9). The answer should evaluate SHI‚Äôs benefits, compare to global models, and propose a reform strategy addressing challenges, aligning with **UHC** goals (HE 4, Section 4).

**Model Answer (500‚Äì600 words)**:  
Malaysia‚Äôs high out-of-pocket (OOP) payments (31.5% of THE in 2021) hinder equitable healthcare access, particularly for low-income and rural populations, exacerbating **health inequities** (HE 4, Section 9; HE 6, Section 2). OOP reliance forces patients to bear costs for consultations, medications, and travel, disproportionately affecting those facing **social determinants** like poverty and limited infrastructure, leading to higher rural IMR and forgone care (HE 6, Section 9). **Social Health Insurance (SHI)** enhances **financial protection** by pooling risks across a mandatory contribution system, reducing individual financial burdens and ensuring access to essential services (HE 5, Section 5). By covering low-income groups, SHI promotes **equity**, aligning with **UHC** goals to provide affordable care (HE 5, Section 9). Thailand‚Äôs Universal Coverage Scheme (UCS), which reduced OOP to 12% of THE, demonstrates SHI‚Äôs success in expanding coverage and reducing disparities, offering a model for Malaysia (HE 5, Section 9).

However, SHI faces challenges like **moral hazard**, where insured patients overuse services (e.g., unnecessary consultations), inflating costs (HE 5, Section 5). **Provider-induced demand** in Malaysia‚Äôs private sector may exacerbate this, as seen in the 40% private outpatient share (HE 3, Section 5). A proposed **financing reform strategy** is to implement a **national SHI system** integrated with **Peka B40**, with the following components:

1. **Mandatory Contributions**: Require income-based contributions, with government subsidies for low-income households, mirroring Thailand‚Äôs UCS (HE 5, Section 9).  
2. **Gatekeeping Mechanisms**: Use primary care referrals to control overuse, addressing **moral hazard** (HE 5, Section 8).  
3. **Standardized Costing**: Adopt **DRG/case-mix costing** to ensure transparent, scalable funding, leveraging Malaysia‚Äôs UNU-CBG Grouper (HE 12, Section 7).  
4. **Rural Focus**: Expand mobile clinics to deliver SHI-covered services, addressing access barriers (HE 6, Section 9).  
5. **Monitoring via NHAs**: Use **National Health Accounts** to track expenditure and ensure equitable allocation (HE 4, Section 9).

This strategy enhances **financial protection** by reducing OOP reliance, ensuring access for rural and low-income groups, and aligns with **UHC** by covering essential services like NCD management (HE 5, Section 9). Compared to Thailand‚Äôs UCS, which achieved near-universal coverage, Malaysia‚Äôs approach must address its dual system‚Äôs private sector dominance (HE 3, Section 5). Challenges include contribution compliance and private provider resistance, which can be mitigated through public awareness campaigns and regulatory enforcement, as seen in **HE 7**‚Äôs **separation of prescribing and dispensing** policy (HE 7, Section 2). By prioritizing **equity** and **financial protection**, this reform supports Malaysia‚Äôs **UHC** goals, ensuring a sustainable, inclusive health system.

**Word Count**: 524

#### Question 3: Applying Economic Evaluations for Non-Communicable Disease Interventions (HE 9, HE 10, HE 12)

**Question**: Non-communicable diseases (NCDs) like diabetes and hypertension are a growing burden in Malaysia. Discuss how **economic evaluations** (e.g., ICER, costing, modeling) can guide the adoption of NCD interventions, focusing on Malaysia-specific challenges (e.g., budget constraints, rural disparities). Propose a framework for prioritizing NCD interventions using **Multi-Criteria Decision Analysis (MCDA)**, drawing on global HTA practices (e.g., NICE).

**Explanation**:  
NCDs like diabetes and hypertension strain Malaysia‚Äôs health system, requiring **economic evaluations** to assess cost-effectiveness (HE 9, Section 4; HE 10, Section 3). **ICER**, **costing** (e.g., DRG, micro-costing), and **modeling** (e.g., Markov models) guide adoption decisions (HE 10, Sections 7‚Äì9). Malaysia‚Äôs challenges include budget constraints and rural disparities (HE 6, Section 2). **MCDA** integrates cost-effectiveness, equity, and feasibility (HE 12, Section 10). The answer should discuss evaluation tools, address challenges, and propose an MCDA framework, referencing global HTA practices like NICE (HE 12, Section 4).

**Model Answer (500‚Äì600 words)**:  
Non-communicable diseases (NCDs) like diabetes and hypertension impose a significant burden on Malaysia‚Äôs healthcare system, with high prevalence and costs straining the 2021 THE of RM 78.2 billion (HE 4, Section 9). **Economic evaluations** guide NCD intervention adoption by assessing **value for money** through tools like **Incremental Cost-Effectiveness Ratio (ICER)**, **costing**, and **modeling** (HE 9, Section 4; HE 10, Section 3). The **ICER** compares additional costs to QALYs gained, enabling **MaHTAS** to prioritize cost-effective interventions (e.g., ICER < RM 100,000 per QALY, HE 12, Section 4). **Costing** methods, such as **DRG/case-mix** for scalable hospital budgets or **micro-costing** for precise trial data, ensure accurate resource estimates (HE 12, Section 7). **Markov models** simulate long-term NCD outcomes, capturing chronic progression (e.g., diabetes complications), critical for Malaysia‚Äôs 10‚Äì20-year horizon needs (HE 10, Section 9). Malaysia‚Äôs challenges include **budget constraints**, limiting funding for high-cost drugs, and **rural disparities**, where access barriers exacerbate inequities (HE 6, Section 2).

A proposed **Multi-Criteria Decision Analysis (MCDA)** framework prioritizes NCD interventions by scoring:

1. **Cost-Effectiveness**: ICER vs. WTP threshold (RM 100,000 per QALY), ensuring value for money (HE 12, Section 4).  
2. **Equity**: Benefits for rural and low-income groups, addressing **Inverse Care Law** (HE 6, Section 2).  
3. **Feasibility**: Infrastructure readiness (e.g., clinics, IT systems), critical for Malaysia‚Äôs uneven healthcare access (HE 12, Section 5).  
4. **Disease Severity**: Prioritizing high-burden NCDs like diabetes (HE 12, Section 10).  
5. **Budget Impact**: Total cost affordability, given Malaysia‚Äôs fiscal constraints (HE 12, Section 6).

For example, a diabetes drug with an ICER of RM 90,000, targeting 1 million patients, scores high on cost-effectiveness but requires assessing budget impact (e.g., RM 200 million annually) and rural access feasibility. **NICE**‚Äôs HTA framework, which uses MCDA to balance cost-effectiveness and equity, informs Malaysia‚Äôs approach by emphasizing transparent criteria weighting (HE 12, Section 4). Implementation involves:

1. **Local Data**: Use Malaysian EQ-5D tariffs for QALYs to reflect local preferences (HE 12, Section 11).  
2. **Stakeholder Engagement**: Involve clinicians and communities to prioritize rural needs (HE 6, Section 9).  
3. **DRG Integration**: Standardize costs via Malaysia‚Äôs UNU-CBG Grouper for scalability (HE 12, Section 7).  
4. **Phased Rollout**: Target high-risk rural areas first to address disparities (HE 6, Section 2).  
5. **Sensitivity Analysis**: Test ICER robustness to ensure reliability (HE 10, Section 8).

This framework addresses Malaysia‚Äôs challenges by balancing **efficiency** with **equity**, ensuring NCD interventions are affordable and accessible, aligning with **UHC** goals (HE 5, Section 9). Global HTA practices like NICE‚Äôs emphasize stakeholder-driven criteria, enhancing policy uptake (HE 12, Section 10).

**Word Count**: 537

#### Question 4: Ensuring Transparent and Policy-Relevant Economic Evaluations (HE 11, HE 12)

**Question**: Transparent reporting via **CHEERS 2022** is critical for policy-relevant economic evaluations in Malaysia‚Äôs health system. Analyze the challenges of ensuring transparency in evaluations for high-cost interventions (e.g., cancer therapies), focusing on common reporting gaps. Propose a framework for Malaysian researchers to align studies with **CHEERS 2022**, incorporating global HTA standards (e.g., HITAP, NICE) to enhance policy uptake.

**Explanation**:  
**CHEERS 2022** ensures **transparent reporting**, critical for **policy relevance** in Malaysia‚Äôs **MaHTAS** evaluations (HE 11, Section 4). High-cost interventions like cancer therapies face reporting gaps (e.g., missing perspective, weak sensitivity analysis), reducing trust and uptake (HE 11, Section 9). A framework should address these gaps, drawing on global HTA standards like NICE and HITAP (HE 11, Section 10; HE 12, Section 10). The answer should analyze challenges, propose a framework, and ensure alignment with **UHC** goals.

**Model Answer (500‚Äì600 words)**:  
Transparent reporting via **CHEERS 2022** is critical for ensuring **policy-relevant economic evaluations** in Malaysia, particularly for high-cost interventions like cancer therapies, which strain budgets (2021 THE: RM 78.2 billion, HE 4, Section 9). **Challenges** include common reporting gaps identified in **HE 11** (Section 9): missing **perspective**, inadequate **sensitivity analysis**, and incomplete **utility valuation**. Omitting perspective (CHEERS Item 8) obscures whether costs include societal impacts (e.g., productivity losses) or only health system costs, making ICERs uninterpretable for **MaHTAS** (HE 11, Section 6). Weak sensitivity analysis (Item 20) fails to test result robustness, critical for high-cost drugs with uncertain outcomes (HE 10, Section 8). Incomplete utility valuation (Item 13) undermines QALY reliability, as Malaysian-specific EQ-5D tariffs are often unavailable, reducing **policy relevance** (HE 12, Section 11). These gaps reduce trust, hindering adoption in Malaysia‚Äôs resource-constrained system, where **equity** for rural and low-income groups is a priority (HE 6, Section 2).

A proposed **framework** for Malaysian researchers to align with **CHEERS 2022** includes:

1. **Standardized Reporting Template**: Adopt a **CHEERS-based checklist** for all evaluations, ensuring all 28 items (e.g., perspective, discount rate) are addressed, mirroring NICE‚Äôs structured HTA submissions (HE 11, Section 5).  
2. **Local Data Integration**: Use Malaysian-specific data (e.g., MOH tariffs, EQ-5D tariffs) to ensure context-specificity, as emphasized in **HE 12** (Section 11).  
3. **Robust Sensitivity Analysis**: Conduct one-way and probabilistic analyses on costs and QALYs, per **HE 10** (Section 8), to address uncertainty, aligning with HITAP‚Äôs rigorous standards (HE 11, Section 10).  
4. **Stakeholder Engagement**: Involve clinicians, patients, and **MaHTAS** in study design to ensure relevance, per CHEERS Item 21 (HE 11, Section 6).  
5. **Visual Aids**: Use cost-effectiveness planes and tornado diagrams to present results clearly, enhancing accessibility for policymakers (HE 10, Section 10; HE 12, Section 3).  
6. **Training Programs**: Build researcher capacity in **CHEERS compliance**, drawing on NICE‚Äôs training models, to improve reporting quality (HE 11, Section 10).

This framework enhances **policy uptake** by ensuring **transparency** and **reproducibility**, critical for **MaHTAS** decisions on cancer therapies (HE 11, Section 10). For example, a transparent evaluation of a RM 120,000 cancer drug with a clear health system perspective and robust sensitivity analysis supports evidence-based adoption, addressing budget constraints (HE 12, Section 6). By aligning with **UHC** goals, the framework prioritizes **equity**, ensuring access for rural patients, reducing OOP burdens (31.5% of THE, HE 4, Section 9), and supporting Malaysia‚Äôs inclusive health system (HE 6, Section 2).

**Word Count**: 522

---
